The value of RWE collected through PSPs

Real-world evidence (RWE) collected through Patient Support Programs (PSPs) provides valuable insights into how treatments perform in everyday settings. In this video, Shazia Hassan, Manager of Market Access and HEOR, explains how PSPs gather rich data on medication adherence, persistence, and patient-reported outcomes to evaluate the real-world impact of therapies. By leveraging this data, we can bridge the gap between clinical trials and real-world experiences, improve patient outcomes, and support better reimbursement and coverage decisions.

Transcript of 'The value of RWE collected through PSPs'

What insights can RWE collected through PSPs provide?

The healthcare landscape is evolving, making it essential to understand how patients interact with treatments in real-world settings.

Clinical trials provide valuable data that occur in controlled environments.

This limits our insights into everyday treatment performance where patients face side effects and lifestyle adjustments.

This is where real-world evidence (or RWE) comes in.

Patient Support Programs (PSPs) are a key source of RWE, assisting patients in accessing and adhering to medications while gathering rich data on their experiences.

Data collection in PSPs is valuable because through ongoing patient engagement and monitoring, insights can be gleaned into medication adherence and persistence, identifying support gaps and enabling treatment success.

Patient reported outcomes collected in PSPs reflect patients' perspectives on their treatment experiences and overall well-being.

This data allows us to evaluate the real-world impact of treatments beyond clinical efficacy.

RWE also plays a crucial role in helping patients access new treatments by helping to demonstrate the value of treatments in the real-world to patients and payers, leading to better reimbursement and coverage policies by decision makers.

By leveraging the high touch nature of PSPs, we can bridge the gap between clinical trials and real-world patient experiences to improve
patient outcomes.

Ultimately, it’s not just about data, it’s about using that data to drive meaningful change in healthcare.

The information provided in this piece does not constitute legal or medical advice. Innomar Strategies Inc. and its parent Cencora, Inc. strongly encourage the audience to review available information related to the topics discussed to rely on their own experience and expertise in making decisions related thereto. Further, the contents of this piece are owned by Innomar Strategies, and reproduction is not permitted without the consent of Innomar Strategies.